Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors
“We are thrilled to welcome Jay to our Board of Directors,” said
“I am excited about the future of Assertio and look forward to helping the Company advance patient care as a member of the Board," said Mr. Galeota.
Mr. Galeota, 52, served as the President and Chief Operating Officer of
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to regulatory approval and clinical development of long-acting cosyntropin, expectations regarding royalties to be received based on sales of NUCYNTA and NUCYNTA ER, expectations regarding potential business opportunities and other risks outlined in the Company's public filings with the
Investor and Media Contact:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.